Idelvion Market Report 2026

Idelvion Market Overview

• The Idelvion market growth in the historic period has been driven by frequent bleeding episodes in hemophilia b, limitations of standard half life factors • Market expansion is supported by increasing use of long acting factors, rising access to home infusion • Growth Driver: Urge In Home-Based Treatment Preference Fueling The Growth Of The Market Due To The Need For Convenient Self-Administration And Improved Quality Of Life • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Idelvion Market?

Idelvion (albutrepenonacog alfa) is a recombinant, extended half-life factor IX replacement therapy used for the treatment and prevention of bleeding episodes in individuals with hemophilia B. It is designed to provide long-lasting clotting factor activity, reducing the need for frequent infusions, offering greater convenience, and improving the quality of life for patients. Idelvion helps to control bleeding and prevent joint damage in those with hemophilia B, a genetic disorder characterized by a deficiency of clotting factor IX. The main indications for idelvion include hemophilia B, prophylactic treatment, and on-demand treatment. Hemophilia B is a genetic disorder where the blood does not clot properly due to a deficiency of clotting factor IX. It is used for pediatrics, adults, and geriatrics and is distributed through hospitals, specialty clinics, home healthcare providers, and retail pharmacies.

What Is The Idelvion Market Growth Forecast?

The growth in the forecast period can be attributed to increasing use of long acting factors, rising access to home infusion, expanding pediatric hemophilia care, supportive reimbursement for prophylaxis, innovation in recombinant clotting factors. Major trends in the forecast period include growing adoption of extended half life factor therapies, shift toward prophylactic hemophilia management, reduced infusion frequency preferences, improved quality of life focus in hemophilia care, expansion of home based treatment models.

Global Idelvion Market Segmentation

1) By Indication: Hemophilia B, Prophylactic Treatment, On-Demand Treatment 2) By Patient Age Group: Pediatrics, Adults, Geriatrics 3) By Distribution Channel: Hospitals, Specialty Clinics, Home Healthcare Providers, Retail Pharmacies

What Are The Drivers Of The Idelvion Market?

The increasing preference for home-based treatment is expected to be propelling the growth of the Idelvion market going forward. Home-based treatment refers to the administration of therapies and medications in a patient's home setting rather than in clinical or hospital environments, enabling greater convenience and independence. The rise in home-based treatment preference is due to patients seeking more control over their treatment schedules, reduced hospital visits, and improved overall quality of life. Idelvion supports home-based treatment by providing extended protection with less frequent dosing, simplified self-administration, and the flexibility required for patients to manage hemophilia B effectively at home. For instance, in June 2025, according to Harmony Healthcare IT, a US-based data management firm, 62% of Americans had utilized telehealth services for their medical needs, while over three-quarters (77%) viewed it as the future of healthcare. Therefore, the increasing preference for home-based treatment is driving the growth of the Idelvion industry. The growing focus on personalized medicine is expected to propel the growth of the idelvion market going forward. Personalized medicine tailor’s treatment and medical care based on an individual’s unique characteristics, preferences, and genetic profile. The growth of personalized medicine is largely fueled by advancements in genomics and data analytics, which enable more targeted treatments. The growing demand for personalized medicine positively impacts Idelvion by fostering tailored treatment approaches for hemophilia B patients, optimizing dosing, and improving therapeutic outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, it was reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the idelvion industry. The healthcare infrastructure improvements are expected to fuel the growth of the idelvion market going forward. Healthcare infrastructure encompasses the critical facilities, resources, and organizational systems needed to deliver healthcare services, including hospitals, clinics, medical equipment, and trained personnel. Improving healthcare infrastructure is essential to enhance the quality of care, increase accessibility, support efficient service delivery, accommodate growing populations, incorporate advanced medical technologies, and address health crises or emergencies effectively. Healthcare infrastructure plays a crucial role in ensuring the availability and proper administration of Idelvion, a recombinant clotting factor IX used for hemophilia B treatment. For instance, in May 2023, according to the Department of Health and Social Care, a UK-based government department, the UK government confirmed that the New Hospital Programme will receive over $25.33 billion (£20 billion) in investment, aiming to fulfill the commitment of building 40 new hospitals in England by 2030. Therefore, healthcare infrastructure improvements are driving the growth of the idelvion industry.

Key Players In The Global Idelvion Market

Major companies operating in the idelvion market are CSL Behring

Regional Insights

North America was the largest region in the idelvion market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Idelvion Market?

The idelvion market consists of sales of prothrombin complex concentrate, immune globulin subcutaneous, and factor XIII products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Idelvion Market Report 2026?

The idelvion market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the idelvion industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.